Xiaoxing Feng

Xiaoxing (Stella) Feng is a seasoned regulatory affairs professional with extensive experience in the pharmaceutical industry. Currently serving as a Senior Manager at Intercept Pharmaceuticals, responsibilities include leading efficacy supplemental NDA submissions, managing clinical study regulatory activities from Phase I to IV, and overseeing EU clinical trial submissions. Prior experience includes regulatory management at Polaris Pharmaceuticals, focusing on electronic submissions to the FDA and UK regulatory bodies. Additional roles as a medical writer and translator have contributed to a robust understanding of clinical documentation and regulatory processes. Xiaoxing holds a Ph.D. in Pharmaceutical Sciences from Washington State University and a Bachelor's Degree in Biological Sciences from Nankai University, complemented by a certificate in Clinical Trials from the University of California, Irvine.